
1. microbiol mol biol rev. 2017 jan 11;81(1). pii: e00047-16. doi:
10.1128/mmbr.00047-16. print 2017 mar.

bromodomains protozoan parasites: evolution, function, opportunities for
drug development.

jeffers v(1), yang c(1), huang s(1), sullivan wj jr(2)(3).

author information: 
(1)department pharmacology toxicology, indiana university school of
medicine, indianapolis, indiana, usa.
(2)department pharmacology toxicology, indiana university school of
medicine, indianapolis, indiana, usa wjsulliv@iu.edu.
(3)department microbiology immunology, indiana university school of
medicine, indianapolis, indiana, usa.

parasitic infections remain one pressing global health concerns of
our day, affecting billions people producing unsustainable economic
burdens. rise drug-resistant parasites created urgent need study
their biology hopes uncovering new potential drug targets. been
established disrupting gene expression interfering lysine
acetylation detrimental survival apicomplexan (toxoplasma gondii and
plasmodium spp.) kinetoplastid (leishmania spp. trypanosoma spp.)
parasites. "readers" lysine acetylation, bromodomain proteins emerged 
as key gene expression regulators promising new class drug target. 
we review recent studies demonstrate essential roles played by
bromodomain-containing proteins parasite viability, invasion, stage
switching present work showing efficacy bromodomain inhibitors as
novel antiparasitic agents. addition, performed phylogenetic analysis 
bromodomain proteins representative pathogens, possess unique
features may specific parasite processes useful future drug
development.

copyright Â© 2017 american society microbiology.

doi: 10.1128/mmbr.00047-16 
pmcid: pmc5312238
pmid: 28077462  [indexed medline]

